Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Aligos Therapeutics (ALGS) EPS (Weighted Average and Diluted) (2021 - 2025)

Aligos Therapeutics' EPS (Weighted Average and Diluted) history spans 5 years, with the latest figure at -$2.01 for Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) rose 84.66% year-over-year to -$2.01; the TTM value through Dec 2025 reached -$8.69, up 58.5%, while the annual FY2025 figure was -$2.45, 88.3% up from the prior year.
  • EPS (Weighted Average and Diluted) reached -$2.01 in Q4 2025 per ALGS's latest filing, up from -$3.04 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $0.81 in Q2 2024 to a low of -$13.1 in Q4 2024.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$2.57, with a median of -$0.84 recorded in 2022.
  • The largest YoY upside for EPS (Weighted Average and Diluted) was 288.37% in 2024 against a maximum downside of 3458.97% in 2024.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.78 in 2021, then soared by 34.62% to -$0.51 in 2022, then skyrocketed by 176.47% to $0.39 in 2023, then crashed by 3458.97% to -$13.1 in 2024, then skyrocketed by 84.66% to -$2.01 in 2025.
  • Per Business Quant, the three most recent readings for ALGS's EPS (Weighted Average and Diluted) are -$2.01 (Q4 2025), -$3.04 (Q3 2025), and -$1.53 (Q2 2025).